Table 3.
In vivo virulence and DAP treatment outcomes
| Group (no. of animals)a |
S. aureus density (log10 CFU/g tissue ± SD)b in: |
||
|---|---|---|---|
| Vegetation | Kidney | Spleen | |
| Without treatment | |||
| UAMS-1 (7) | 7.30 ± 1.01 | 5.59 ± 0.65 | 5.60 ± 0.41 |
| ΔlytS mutant (7) | 7.65 ± 0.52 | 5.21 ± 0.88 | 5.35 ± 0.39 |
| ΔlytS Comp (7) | 7.12 ± 0.87 | 4.63 ± 0.86§ | 4.93 ± 0.70 |
| ΔlrgAB mutant (7) | 6.89 ± 0.93 | 4.52 ± 0.80§ | 4.97 ± 0.82 |
| DAP treatment (12 mg/kg, i.v., once daily, 3 days) | |||
| UAMS-1 (6) | 3.31 ± 0.59† | 2.67 ± 1.09† | 2.10 ± 0.65† |
| ΔlytS mutant (7) | 1.74 ± 0.69†* | 0.97 ± 0.71†* | 0.96 ± 0.58†* |
| ΔlytS Comp (7) | 2.56 ± 0.52† | 1.53 ± 0.65†¥ | 1.63 ± 0.75† |
| ΔlrgAB mutant (7) | 4.48 ± 1.85† | 4.33 ± 1.01¥ | 4.50 ± 1.27¥ |
a
Comp, complemented strain.
b
†, P < 0.05 versus same strain without DAP treatment; §, P < 0.05 versus UAMS-1 without DAP treatment; *, P < 0.001 versus UAMS-1 with DAP treatment; ¥, P < 0.05 versus UAMS-1 with DAP treatment.